Pfizer (NYSE:PFE) Reaches New 1-Year High – Should You Buy?

Pfizer Inc. (NYSE:PFE)’s stock price reached a new 52-week high during mid-day trading on Friday. The stock traded as high as $30.65 and last traded at $30.3440, with a volume of 3,118,623 shares changing hands. The stock had previously closed at $29.95.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial for ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result strengthens the drug’s potential to expand within Pfizer’s oncology portfolio. How Investors May Respond To Pfizer (PFE) Phase 3 Cancer Trial Win
• Positive Sentiment: The FDA expanded approval for TALZENNA plus XTANDI in certain men with metastatic hormone-sensitive prostate cancer, adding another potential revenue opportunity for Pfizer’s established medicines. How Investors May Respond To Pfizer (PFE) Phase 3 Cancer Trial Win
• Positive Sentiment: Pfizer agreed to work with Edison Scientific to accelerate research and development. While financial details were not provided, the collaboration could improve the efficiency of future drug discovery. Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on PFE shares. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. BMO Capital Markets lowered their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. HSBC boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, September 10th. JPMorgan Chase & Co. lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 9th. Finally, Cantor Fitzgerald upped their target price on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Thursday, October 8th. Five equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.72.

Pfizer Trading Up 1.2%

The firm has a market cap of $172.76 billion, a PE ratio of 39.80, a P/E/G ratio of 2.00 and a beta of 0.32. The company’s fifty day moving average price is $28.49 and its two-hundred day moving average price is $26.76. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 5.7%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE bought a new position in shares of Pfizer in the second quarter valued at about $1,049,602,000. BlackRock Inc. raised its position in Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after purchasing an additional 31,412,883 shares during the last quarter. Nykredit A S bought a new position in Pfizer during the 2nd quarter worth $205,774,000. Assenagon Asset Management S.A. increased its position in shares of Pfizer by 96.0% during the second quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock worth $286,609,000 after buying an additional 5,829,204 shares during the period. Finally, State Street Corp grew its stake in Pfizer by 1.8% during the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after purchasing an additional 5,501,032 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.